Evaluate the Pharmacokinetic Characteristics and Safety/Tolerability of YNP-1807 Compared to Lyrica® After Oral Administration Adult Volunteers

NCT03261427 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

17

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy

Interventions

DRUG: Lyrica 150Mg Capsule
DRUG: YNP-1807 330Mg Tablet

Sponsor

Yungjin Pharm. Co., Ltd.